Val-Cit-PAB-DEA-Dxd (compound 81) is a cleavable drug-linker conjugate designed for constructing antibody-drug conjugates (ADCs). It incorporates the topoisomerase I inhibitor Dxd, enabling targeted cytotoxicity. This reagent is widely used in ADC research and development for both in vitro and in vivo preclinical studies.